PT951908E - Metodo para o tratamento de impotencia devida a lesao da medula espinal - Google Patents

Metodo para o tratamento de impotencia devida a lesao da medula espinal

Info

Publication number
PT951908E
PT951908E PT99301085T PT99301085T PT951908E PT 951908 E PT951908 E PT 951908E PT 99301085 T PT99301085 T PT 99301085T PT 99301085 T PT99301085 T PT 99301085T PT 951908 E PT951908 E PT 951908E
Authority
PT
Portugal
Prior art keywords
spinal cord
lesion
treatment
impotence due
male
Prior art date
Application number
PT99301085T
Other languages
English (en)
Inventor
Maytom Murray Craig
Osterloh Ian Howard
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of PT951908E publication Critical patent/PT951908E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Electrotherapy Devices (AREA)
PT99301085T 1998-02-23 1999-02-15 Metodo para o tratamento de impotencia devida a lesao da medula espinal PT951908E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7558098P 1998-02-23 1998-02-23

Publications (1)

Publication Number Publication Date
PT951908E true PT951908E (pt) 2005-01-31

Family

ID=22126701

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99301085T PT951908E (pt) 1998-02-23 1999-02-15 Metodo para o tratamento de impotencia devida a lesao da medula espinal

Country Status (17)

Country Link
US (1) US20060040935A1 (pt)
EP (1) EP0951908B1 (pt)
JP (1) JPH11315025A (pt)
KR (1) KR19990072798A (pt)
AT (1) ATE279194T1 (pt)
AU (1) AU755402B2 (pt)
CA (1) CA2262268C (pt)
DE (1) DE69921008T2 (pt)
DK (1) DK0951908T3 (pt)
ES (1) ES2226281T3 (pt)
HU (1) HUP9900438A3 (pt)
IL (1) IL128532A0 (pt)
MY (1) MY133446A (pt)
NZ (1) NZ334333A (pt)
PT (1) PT951908E (pt)
TW (1) TW542719B (pt)
ZA (1) ZA991393B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
DE19834506A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
EP1173167A4 (en) 1999-04-30 2004-07-14 Lilly Icos Llc TREATMENT OF FEMALE SEXUAL STIMULATION DISORDERS
EP1244673A2 (de) 1999-12-24 2002-10-02 Bayer Aktiengesellschaft Imidazo[1,3,5]triazinone und ihre verwendung
KR20010016165A (ko) * 2000-11-16 2001-03-05 정순학 성기능 장애 치료를 위한 피부에 적용하는 제제
KR100393160B1 (ko) * 2001-06-14 2003-07-31 한국과학기술연구원 신규한 피라졸로피리미딘티온 유도체, 그의 제법 및발기부전 치료제로서의 용도
WO2002102385A1 (en) * 2001-06-14 2002-12-27 Sampad Bhattacharya Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
CN101027061B (zh) 2004-05-11 2014-03-12 情感智能有限责任公司 药物制剂及其在治疗女性性功能障碍中的应用
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2008142396A1 (en) * 2007-05-18 2008-11-27 Anthony Denis Maher Methods of assessing male fertility using a uridine marker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
DK0951908T3 (da) 2004-12-27
HU9900438D0 (en) 1999-04-28
CA2262268C (en) 2003-07-29
MY133446A (en) 2007-11-30
ES2226281T3 (es) 2005-03-16
TW542719B (en) 2003-07-21
IL128532A0 (en) 2000-01-31
JPH11315025A (ja) 1999-11-16
EP0951908A3 (en) 2000-08-16
HUP9900438A2 (hu) 2000-03-28
US20060040935A1 (en) 2006-02-23
CA2262268A1 (en) 1999-08-23
DE69921008D1 (de) 2004-11-18
ZA991393B (en) 2000-08-22
KR19990072798A (ko) 1999-09-27
AU1839099A (en) 1999-09-09
ATE279194T1 (de) 2004-10-15
NZ334333A (en) 2000-11-24
AU755402B2 (en) 2002-12-12
HUP9900438A3 (en) 2002-01-28
EP0951908A2 (en) 1999-10-27
EP0951908B1 (en) 2004-10-13
DE69921008T2 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
PA8476301A1 (es) Formulaciones intranasales para tratar trastornos sexuales
IL128532A0 (en) Method of treating impotence due to spinal cord injury
ZA200206612B (en) Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction.
PT1073658E (pt) Inibidores de ogmp pdes de pirazolopirimidinona para o tratamento da disfuncao sexual
BR0316753A (pt) Método de tratamento para disfunção sexual
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
ECSP034519A (es) Inhibidores de xantina fosfodiesterasa v
BG105664A (en) Use of apomophines for the treatment of organic erectile dysfunction in males
EP1108426A3 (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence
BR9810981A (pt) Medicamento contendo ioimbina e arginina para tratamento de disfunção erétil
PT1109814E (pt) 5-heterociclil pirazol¬4,3-d|pirimidina-7-onas para o tratamento da disfuncao erectil masculina
NO20055187D0 (no) Fremgangsmate for behandling og forebygging av lavere urinkanal symptomer
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
NO995008L (no) En transuretral anordning
WO2004069254A3 (en) Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders
WO2005051368A3 (en) Phosphodiesterase v inhibitor formulations
WO2002011665A3 (fr) Association d'une purine et d'un ains pour le traitement des dysfonctions sexuelles
MD1979F1 (en) Method of secondary cataract treatment
WO1996036339A3 (en) Use of dihydrotestosterone compounds for treating male sexual dysfunction
BR0314364A (pt) Uso de inibidores de pde iv para tratar angiogênese
IL166273A0 (en) Methods of treatment of male erectile dysfunction
ES2092685T3 (es) Uso de atipamezol para el tratamiento de impotencia sexual masculina.
WO2005021583A3 (en) METHODS FOR IDENTIFYING, TREATING, AND INDUCING INFERTILITY USING SMC1β
ECSP993027A (es) Formulaciones intranasales para trastornos sexuales
GB9928178D0 (en) Agent for the treatment of male and female sexual dysfunction